Soleno Therapeutics (SLNO) CDO awarded RSUs and 4,700 stock options

Rhea-AI Filing Summary

Soleno Therapeutics reported an equity compensation grant to its Chief Development Officer, Joshi Manher. On January 21, 2026, Manher was awarded 4,100 restricted stock units (RSUs) of common stock at a price of $0 per unit, increasing his directly held RSUs tied to common stock to 20,171 following the grant. Each RSU represents the right to receive one share of common stock, and 100% of this new RSU grant is scheduled to vest on December 15, 2027, subject to continued service under the company’s 2014 Equity Incentive Plan.

On the same date, Manher also received an employee stock option covering 4,700 shares of common stock with an exercise price of $43.65 per share. The option vests in equal monthly installments, with 1/48th of the shares vesting on February 1, 2026 and on each one-month anniversary thereafter, conditioned on continued service. All reported holdings in this filing are listed as direct ownership.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Joshi Manher

Role Chief Development Officer

Type	Security	Shares	Price	Value
Grant/Award	Employee stock option (right to buy)	4,700	$0.00	--
Grant/Award	Common Stock	4,100	$0.00	--

Holdings After Transaction: Employee stock option (right to buy) — 4,700 shares (Direct); Common Stock — 20,171 shares (Direct)

Footnotes (1)

1. These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. 100% of the RSUs shall vest on December 15, 2027, subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2014 Equity Incentive Plan) through such date. These securities are RSUs. Each RSU represents a contingent right to receive one share of Common Stock, subject to the applicable vesting schedule and conditions of each RSU. 1/48th of the shares subject to the option shall vest on February 1, 2026 and each one-month anniversary thereafter, subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2014 Equity Incentive Plan) through each such date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Joshi Manher

(Last) (First) (Middle)

100 MARINE PARKWAY, SUITE 400

(Street)

REDWOOD CITY CA 94065

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
SOLENO THERAPEUTICS INC [ SLNO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Development Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/21/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/21/2026		A		4,100(1)	A	$0	20,171(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee stock option (right to buy)	$43.65	01/21/2026		A		4,700		(3)	01/21/2036	Common Stock	4,700	$0	4,700	D

Explanation of Responses:

1. These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. 100% of the RSUs shall vest on December 15, 2027, subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2014 Equity Incentive Plan) through such date.

2. These securities are RSUs. Each RSU represents a contingent right to receive one share of Common Stock, subject to the applicable vesting schedule and conditions of each RSU.

3. 1/48th of the shares subject to the option shall vest on February 1, 2026 and each one-month anniversary thereafter, subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2014 Equity Incentive Plan) through each such date.

	/s/ Anish Bhatnagar, Attorney-in-Fact	01/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What equity awards did Soleno Therapeutics (SLNO) grant to Joshi Manher on January 21, 2026?

On January 21, 2026, Soleno Therapeutics granted Chief Development Officer Joshi Manher 4,100 RSUs of common stock at $0 per unit and an employee stock option for 4,700 shares of common stock with an exercise price of $43.65 per share.

How do the new RSUs for Joshi Manher at Soleno Therapeutics (SLNO) vest?

The 4,100 RSUs granted to Joshi Manher each represent a right to receive one share of common stock. 100% of these RSUs are scheduled to vest on December 15, 2027, as long as he continues to be a service provider under Soleno’s 2014 Equity Incentive Plan through that date.

What is the vesting schedule for Joshi Manher7s 4,700 Soleno stock options?

The 4,700-share employee stock option granted to Joshi Manher vests in 48 equal monthly installments. 1/48th of the option shares vest on February 1, 2026, and an additional 1/48th vests on each one-month anniversary thereafter, subject to continued service.

What are Joshi Manher7s Soleno common stock-related holdings after this Form 4?

After the January 21, 2026 grants, Joshi Manher beneficially owns 20,171 RSUs tied to Soleno common stock and 4,700 employee stock options, all reported as direct ownership.

What role does Joshi Manher hold at Soleno Therapeutics (SLNO)?

Joshi Manher is reported as an officer of Soleno Therapeutics, serving as the company7s Chief Development Officer in this Form 4.

Does the Form 4 indicate any sale of Soleno (SLNO) shares by Joshi Manher?

No sales are reported in this Form 4. The filing shows only acquisitions of RSUs and an employee stock option, each at a price of $0 per unit for the RSUs and with an exercise price of $43.65 per share for the option.